Media Contact:
Stephen Majors
Head of Global Communications
smajors@alliancerm.org
Washington, DC
The voluntary model recognizes that transformative, durable, and potentially curative gene therapies require innovative thinking about access, payment, and healthcare delivery.
Washington, DC
Today, the FDA approved two gene therapies to treat sickle cell disease, marking the biggest day in the history of gene therapy and a seminal moment in the history of biotechnology and human health.
Carlsbad, CA
New analysis shows that durable cell and gene therapies have clinical success rates between two and three times higher than other types of treatments.
Carlsbad, CA
The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines, today announced the election of its 2024 Board of Directors.
